You are here

Novartis

Novartis looks at offloading its generic pills business in U.S. as market continues to decline

Novartis looks at offloading its generic pills business in U.S. as market continues to decline

Fierce Pharma

Flag link:

Anti-aging startup ResTORbio gets $40M to fuel Phase IIb study

Anti-aging startup ResTORbio gets $40M to fuel Phase IIb study

Endpoints

clinical trials

Flag link:

Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'

Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'

Forbes

Flag link:

One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology

One big Novartis takeaway from Entresto's slow start? Heart failure doesn't work like oncology

Fierce Pharma

Flag link:

Novartis looks to poach Advair patients with positive Ultibro switching data

Novartis looks to poach Advair patients with positive Ultibro switching data

Fierce Pharma

Ultibro Breezhaler

Flag link:

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

Endpoints

Flag link:

Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations

Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations

Fierce Pharma

Flag link:

What to expect from Vas Narasimhan, next Novartis CEO

What to expect from Vas Narasimhan, next Novartis CEO

GoinPharma

Flag link:

Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market

Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market

Endpoints

Flag link:

Novartis spotlights its top 4 blockbuster late-stage pipeline projects

Novartis spotlights its top 4 blockbuster late-stage pipeline projects

Endpoints

wet age-related macular degeneration

Flag link:

Novartis outlines its full case on why RTH258 can carve out a big piece of the AMD market held by Regeneron

Novartis outlines its full case on why RTH258 can carve out a big piece of the AMD market held by Regeneron

Endpoints

wet age-related macular degeneration

Flag link:

Novartis strengthens autoimmune indications for Cosentyx

Novartis strengthens autoimmune indications for Cosentyx

PM Live

autoimmune disease

psoriatic arthritis

ankylosing spondylitis

Flag link:

Novartis takes fight to Pfizer's Ibrance with new Kisqali data

Novartis takes fight to Pfizer's Ibrance with new Kisqali data

Yahoo/Reuters

Flag link:

With new FDA nod, Roche's Alecensa set to challenge Pfizer, Novartis in first-line lung cancer

With new FDA nod, Roche's Alecensa set to challenge Pfizer, Novartis in first-line lung cancer

Fierce Pharma

Flag link:

Novartis seeks European approval for cell therapy Kymriah

Novartis seeks European approval for cell therapy Kymriah

Reuters

diffuse large B-cell lymphoma

acute lymphoblastic leukemia

Flag link:

Novartis and Amgen launch new Alzheimer’s study

Novartis and Amgen launch new Alzheimer’s study

Endpoints

Alzheimer's disease

clinical trials

Flag link:

Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis

Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis

Yahoo/Motley Fool

Juno Therapeutics

Flag link:

Novartis Weighs Sale of Dermatology Generics Business

Novartis Weighs Sale of Dermatology Generics Business

Bloomberg

Flag link:

Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on

Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on

Endpoints

diffuse large B-cell lymphoma

Flag link:

Pages